ArticleFrontiers in cardiovascular medicine2025
Identifying and validating hypoxia- and metabolism-related hub genes and cell communication in atherosclerosis.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring histone acetylation in ischemic stroke: CREBBP and CKAP4 as candidate biomarkers linked to histone acetylation networks.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atherosclerosis (AS) is a multifactorial disorder characterized by plaque formation, with hypoxia and metabolic pathways playing central roles in its pathogenesis. However, the differentially expressed metabolism-hypoxia-related genes (DE-MH-RGs) contributing to AS remain largely undefined. This study aimed to characterize DE-MH-RGs to uncover their potential regulatory mechanisms in AS. Results: Single-cell sequencing data, AS-related datasets, 200 hypoxia-related genes (HRGs), and 2,752 metabolism-related genes (MRGs) were employed for analysis. Single-cell sequencing identified distinct cell subpopulations, and differential gene expression was assessed between the AS and normal groups in GSE100927. DE-MH-RGs were determined by intersecting differentially expressed HRGs and MRGs. Functional enrichment of DE-MH-RGs was conducted through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, followed by protein-protein interaction (PPI) network construction. Hub genes were identified using least absolute shrinkage and selection operator (LASSO) logistic regression and further validated by gene set enrichment analysis (GSEA) and Gene Set Variation Analysis (GSVA). Immune feature analysis assessed immune cell proportions and identified potential drug candidates. Hub genes were also pinpointed in single-cell data (GSE159677) using ReactomeGSA, cell communication, and pseudotime analyses. Single-cell analysis revealed five distinct subpopulations-T lymphocytes, endothelial cells, macrophages, vascular smooth muscle cells (VSMCs), and B lymphocytes-and 141 DE-MH-RGs. Enrichment analysis highlighted the association of these genes with circulatory system pathways, including vascular functions and responses to oxygen and hypoxia. The hub genes, RYR2, ABCC9, KCNJ2, EGFR, and SLC7A8, exhibited strong diagnostic potential. GSVA analysis linked the hub genes to several metabolic pathways. Thirteen immune cell types showed significant differences between normal and AS samples. Potential therapeutic agents, such as afatinib, were identified. The hub genes were primarily located in VSMCs. Most AS cells displayed low differentiation levels. Conclusions: Transcriptomic data from AS identified key hub genes related to hypoxia and metabolism, offering valuable insights for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.